Vifor Pharma AG (VIFN)

Switzerland

Currency in CHF

166.15

0.00(0.00%)

Closed·22/12

Day's Range

165.00

166.50

52 wk Range

165.00

166.50

VIFN Income Statement

Explore the detailed Vifor Pharma AG income statement, offering a comprehensive view of the company’s financial performance. Review essential metrics such as revenue, gross profit, operating income, and net income over selected periods. This page provides a clear breakdown of profitability and operational efficiency, helping you evaluate Vifor Pharma AG's growth trends and overall financial health.

Advanced Income Statement

Period Ending:

2012

31/12

2013

31/12

2014

31/12

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

Total Revenues

aa.aa

1,378

1,638.5

1,754.3

1,761.7

1,812.1

Total Revenues Growth

aa.aa

+9.91%

+18.9%

+7.07%

+0.42%

+2.86%

Cost Of Revenues

aa.aa

517.9

648.7

700.8

701.2

671.8

Gross Profit

aa.aa

860.1

989.8

1,053.5

1,060.5

1,140.3

Gross Profit Growth

aa.aa

+6.45%

+15.08%

+6.44%

+0.66%

+7.52%

Gross Profit Margin %

aa.aa

62.42%

60.41%

60.05%

60.2%

62.93%

Other Operating Expenses, Total

aa.aa

725.9

762.4

779.9

747.3

762.8

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+26.99%	+5.03%	+2.3%	-4.18%	+2.07%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	185.1	206.4	212	193.8	225.1
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	546.1	566.7	573.3	559.5	543.9
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-5.3	-10.7	-5.4	-6	-6.2

Operating Income

aa.aa

134.2

227.4

273.6

313.2

377.5

Operating Income Growth

aa.aa

-43.23%

+69.45%

+20.32%

+14.47%

+20.53%

EBIT Margin %

aa.aa

9.74%

13.88%

15.6%

17.78%

20.83%

Net Interest Expenses

aa.aa

-8.1

2.8

9.8

Net Interest Expenses Growth

aa.aa

-50%

+161.73%

-44%

+250%

-89.8%

Interest Expense, Total

aa.aa

-25.1

-6.8

-9

-7.7

-9

Interest And Investment Income

aa.aa

11.8

17.5

Other Non Operating Expenses, Total

aa.aa

-0.5

-17.7

-36.4

-13.3

EBT, Excl. Unusual Items

aa.aa

125.6

269.4

258.7

286.6

365.2

Gain (Loss) On Sale Of Assets

aa.aa

2.3

31.1

-69.7

Other Unusual Items, Total

aa.aa

-53

-25.6

EBT, Incl. Unusual Items

aa.aa

125.6

269.4

261

264.7

311.7

EBT, Incl. Unusual Items Growth

aa.aa

-44.23%

+114.49%

-3.12%

+1.42%

+17.76%

EBT, Incl. Unusual Items Margin

aa.aa

9.11%

16.44%

14.88%

15.03%

17.2%

Income Tax Expense

aa.aa

1.6

38.1

27.1

46.3

Net Income to Company

aa.aa

1,237

244.4

273.8

458.5

263.2

Minority Interest

aa.aa

-89.9

-92

-114.7

-98.9

-118.8

Net Income

aa.aa

1,147.1

152.4

159.1

359.6

144.4

Net Income Growth

aa.aa

+384.01%

-86.71%

+4.4%

+126.02%

-59.84%

Net Income Margin %

aa.aa

83.24%

9.3%

9.07%

20.41%

7.97%

Preferred Dividend and Other Adjustments

aa.aa

Net Income to Common Excl. Extra Items

aa.aa

34.1

152.4

108.2

138.7

146.6

Basic EPS - Continuing Operations

aa.aa

0.53

2.35

1.67

2.14

2.26

Basic EPS - Continuing Operations Growth

aa.aa

-76.82%

+346.66%

-29.01%

+28.23%

+5.67%

Diluted EPS - Continuing Operations

aa.aa

0.52

2.34

1.66

2.13

2.25

Diluted EPS - Continuing Operations Growth

aa.aa

-77.09%

+350%

-29.06%

+28.31%

+5.63%

Basic Weighted Average Shares Outstanding

aa.aa

64.81

64.85

64.86

64.84

64.86

Diluted Weighted Average Shares Outstanding

aa.aa

64.92

65.02

65.05

Dividend Per Share

aa.aa

Dividend Per Share Growth

aa.aa

EBITDA

aa.aa

276.3

387.9

463

513.3

549.5

EBITDA Growth

aa.aa

-13.55%

+40.39%

+19.36%

+10.86%

+7.05%

EBITDA Margin %

aa.aa

20.05%

23.67%

26.39%

29.14%

30.32%

EBIT

aa.aa

134.2

227.4

273.6

313.2

377.5

* In Millions of CHF (except for per share items)

US 30

42,287.00

-35.8

-0.08%

US 500

5,913.40

-3.5

-0.06%

Dow Jones

42,322.75

+271.69

+0.65%

S&P 500

5,916.93

+24.35

+0.41%

Nasdaq

19,112.32

-34.49

-0.18%

S&P 500 VIX

17.83

-0.79

-4.24%

Dollar Index

100.53

-0.199

-0.20%

Market Movers

Name	Last	Chg. %	Vol.
NVDA	134.83	-0.38%	226.63M
UNH	274.35	-10.93%	121.85M
TSLA	342.82	-1.40%	97.88M
AMZN	205.17	-2.42%	64.35M
AAPL	211.45	-0.41%	45.03M
MSFT	453.13	+0.04%	21.99M
META	643.88	-2.35%	14.34M

Trending Stocks

Name	Last	Chg. %	Vol.
UNH	274.35	-10.93%	121.85M
NVDA	134.83	-0.38%	226.63M
TSLA	342.82	-1.40%	97.88M
BABA	123.90	-7.57%	35.44M
SMCI	43.96	-2.31%	87.04M

Most Undervalued Stocks

Name	Last	Upside	Fair Value
Aaaaaa	308.86	+43.85%	444.30
Aaaaaaaaaaa	35.33	+41.19%	49.88
A Aaaaaaaaaa Aaa	75.96	+36.86%	103.96
Aaaaaaa A	92.96	+30.21%	121.04
Aa Aa Aa	108.58	+28.08%	139.07
Aaaaa Aaaaaaa	142.26	+26.00%	179.25
Aaaaaaa Aaaaaaaaaaa	27.49	+24.54%	34.24

Name	Last	Upside	Fair Value
Aaaaaa	308.86	+43.85%	444.30
Aaaaaaaaaaa	35.33	+41.19%	49.88
A Aaaaaaaaaa Aaa	75.96	+36.86%	103.96
Aaaaaaa A	92.96	+30.21%	121.04
Aa Aa Aa	108.58	+28.08%	139.07
Aaaaa Aaaaaaa	142.26	+26.00%	179.25
Aaaaaaa Aaaaaaaaaaa	27.49	+24.54%	34.24

See full list

Install Our AppScan QR code to install app

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Name	Last	Chg. %	Vol.
STE	246.88	+8.52%	1.15M
DG	92.99	+6.03%	3.89M
FMC	39.22	+5.49%	2.75M
HCA	385.50	+4.90%	3.05M
AWK	140.37	+4.89%	2.53M
CSCO	64.26	+4.85%	60.72M
VTRS	8.79	+4.39%	16.49M

Name	Last	Chg. %	Vol.
FI	159.13	-16.19%	23.34M
UNH	274.35	-10.93%	121.85M
MSTR	397.03	-4.73%	14.67M
FSLR	186.18	-3.52%	5.98M
MPWR	710.32	-3.26%	981.49K
UAL	76.54	-3.10%	9.18M
APP	366.61	-2.64%	6.32M

Popular Searches

Please try another search

Vifor Pharma AG (VIFN)

VIFN Income Statement

Trending Stocks